Quintiles Names Late Phase Ops Head

Dr. Cynthia L. Verst has been named Global Head of Late Phase Operations at Quintiles. In this role, she will leads the company’s dedicated business that bridges the gap between peri-approval and commercialization of marketed therapies.

“Dr. Verst brings a dynamic leadership style and record of success in establishing and growing Late Phase operations,” said John Ratliff, Quintiles’ president and chief operating officer. “Biopharma companies have traditionally designed studies with a focus on meeting regulatory requirements. Today, as biopharma adapts to the changing healthcare landscape we call the New Health, stakeholders demand real-world evidence. Our customers need to take a more proactive approach to collecting this evidence, and we are well positioned to help them demonstrate product value using robust data from real-world settings.”

Dr. Verst has 17 years of biopharma experience and a track record of late phase operational leadership and innovation. Most recently, she was senior vice president, Global Late Phase Research, for Ingenix, where she and her team successfully established that business unit. Previously, she led Kendle’s global Late Phase business unit. She began her biopharma career at Procter & Gamble Pharmaceuticals as section head in its North American Medical and Technical Affairs group, successfully leading the Phase IIIB/IV research requirements of marketed products.

Quintiles’ late phase offerings include resources to meet both safety and efficacy requirements, incorporating a combination of scientific rationale and operational models, direct access to patients, tailored data management, dedicated statistical analysis teams, and integration among clinical, consulting and commercial capabilities.